A randomized controlled trial of low-dose recombinant human interferons alpha-2b nasal spray to prevent acute viral respiratory infections in military recruits

Vaccine. 2010 Jun 17;28(28):4445-51. doi: 10.1016/j.vaccine.2010.03.062. Epub 2010 Apr 13.

Abstract

The military population has a high disease burden of acute viral respiratory infections in China. To assess the efficacy and safety of a low-dose recombinant human interferon alpha-2b (rIFNalpha-2b) nasal spray in preventing acute viral respiratory infections in military population, we performed this randomized controlled trial. The results showed that application of the rIFNalpha-2b nasal spray had the benefits in prevention of infections caused by influenza A virus, influenza B virus parainfluenza viruses 1-3 and adenovirus species B. However, no benefit was seen in preventing respiratory syncytial virus. No severe adverse events were reported. Therefore, the rIFNalpha-2b nasal spray was effective and well tolerated for preventing common viral respiratory infections in the military recruits.

Publication types

  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Intranasal
  • Adolescent
  • Antibodies, Viral / blood
  • Antiviral Agents / administration & dosage
  • Antiviral Agents / therapeutic use*
  • China
  • Double-Blind Method
  • Humans
  • Immunoglobulin M / blood
  • Interferon alpha-2
  • Interferon-alpha / administration & dosage
  • Interferon-alpha / therapeutic use*
  • Male
  • Military Personnel*
  • Recombinant Proteins
  • Respiratory Tract Infections / drug therapy
  • Respiratory Tract Infections / prevention & control*
  • Respiratory Tract Infections / virology
  • Virus Diseases / drug therapy
  • Virus Diseases / prevention & control*
  • Young Adult

Substances

  • Antibodies, Viral
  • Antiviral Agents
  • Immunoglobulin M
  • Interferon alpha-2
  • Interferon-alpha
  • Recombinant Proteins